Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Solasia Gets Japan Rights to Isofol’s Cancer Drug
August 17, 2020
- Nippon Shinyaku’s DMD Treatment Approved in US
August 17, 2020
- AbbVie Japan Alters Company Rules for Same-Sex, Common-Law Marriages
August 17, 2020
- Fujifilm-Sponsored Avigan Trial to Complete Enrollment on Aug. 16
August 12, 2020
- Biosimilars Showing Accelerated Uptick in Japan, Doctor Fee Incentive as Tailwind
August 12, 2020
- 2 Employees Infected with Coronavirus: Pfizer Japan
August 12, 2020
- Denka to Launch Rapid Antigen Test Kit for COVID-19 on August 13
August 12, 2020
- Xarelto OD Tablets Approved, Specially Developed for Japan: Bayer
August 12, 2020
- Taiho Confirms COVID-19 Cluster at Its Training Center, 8 Test Positive
August 12, 2020
- Takeda Pairs with Novavax to Roll Out Coronavirus Vaccine in Japan, Wins 30 Billion Yen in Govt Funding
August 11, 2020
- Aducanumab Accepted for FDA Review with Priority Tag; Target Date Set for March 7
August 11, 2020
- Otsuka’s 1st Half Pharma Sales Rise 7.6% as 4 Global Brands Fare Well
August 11, 2020
- Mundipharma’s Sedative Agent Anerem Now Available in Japan
August 11, 2020
- Japan Ethical Drug Sales Up 0.9% in June: Crecon
August 11, 2020
- Daiichi Sankyo, AstraZeneca to Team Up for PI of Patritumab Deruxtecan/Tagrisso Combo in EGFR-Mutated NSCLC
August 11, 2020
- Japan’s Diabetic Market to Shrink after Peaking in FY2023: Yano Research
August 11, 2020
- Telomelysin-Keytruda Combo Trial to Begin in US for Head and Neck Cancer: Oncolys
August 11, 2020
- Axcelead Chief Says Small-Molecule Drug Targets More than Doubled in Last Few Years; IPO Eyed in 4-5 Years
August 7, 2020
- Sumitomo Dainippon Eyes 100 Billion Yen Sales from Frontier Biz: President
August 7, 2020
- Some Firms Curbing Supplies of Ethical Povidone-Iodine Products after Osaka COVID-19 Data
August 7, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…